Medsamic (Tranexamic Acid)

Tranexamic Acid is an antifibrinolytic used to control bleeding in several clinical settings.

• Hemophilia‑associated bleeding: Reduces bleeding episodes by stabilizing clots.
• Menorrhagia: Decreases menstrual blood loss and improves quality of life.
• Trauma‑related hemorrhage: Controls acute bleeding following injury.
• Surgical bleeding: Minimizes intra‑operative blood loss and transfusion requirements.

• Tranexamic Acid competitively inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis. By blocking plasmin formation, it preserves fibrin clot integrity and promotes hemostasis in tissues where bleeding is present, without directly affecting platelet function or the coagulation cascade.

Adverse reactions may occur with tranexamic acid administration.

Common Side Effects

• Nausea: Mild to moderate stomach upset.
• Vomiting: May accompany nausea.
• Diarrhea: Loose stools reported.
• Headache: Transient cranial discomfort.
• Dizziness: Light‑headed sensation.
• Injection site reactions: Redness or mild pain.

Serious or Rare Side Effects

• Thromboembolic events: Deep vein thrombosis or pulmonary embolism.
• Seizures: Particularly at high plasma concentrations.
• Visual disturbances: Blurred vision or retinal changes.
• Hypotension: Sudden drop in blood pressure.
• Severe allergic reactions: Anaphylaxis or angioedema.
• Renal impairment: Decreased kidney function in susceptible patients.

Before using tranexamic acid, consider the following safety measures.

• Assess thrombotic risk: Evaluate history of clotting disorders.
• Monitor renal function: Adjust use in patients with kidney impairment.
• Use caution in pregnancy: Limited data, weigh benefits against potential risks.
• Avoid in active disseminated intravascular coagulation: May exacerbate condition.
• Concomitant anticoagulants: Adjust therapy to prevent excessive bleeding.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Tranexamic acid can interact with several medication classes.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin, heparin): Increased risk of thrombosis.
• Hormonal contraceptives: Potential additive pro‑thrombotic effect.
• Thrombolytic agents (e.g., alteplase): Counteract intended fibrinolysis.

Moderate Interactions (Monitor Closely)

• NSAIDs: May increase bleeding tendency.
• Antiplatelet drugs (e.g., aspirin, clopidogrel): Enhanced anticoagulant effect.
• Diuretics: May affect renal clearance of tranexamic acid.